vegf 165 protein Search Results


96
R&D Systems recombinant human homodimeric vegf a 165
Recombinant Human Homodimeric Vegf A 165, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human homodimeric vegf a 165/product/R&D Systems
Average 96 stars, based on 1 article reviews
recombinant human homodimeric vegf a 165 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

97
R&D Systems recombinant human vascular endothelial growth factor vegf
FAK inhibitors decrease number of viable <t>endothelial</t> cells in a dose‐dependent manner. HUVEC were incubated with various concentrations of either PF‐228 (A) or FI14 (B) in the presence of <t>VEGF.</t> Cells treated with vehicle (DMSO) were used ...
Recombinant Human Vascular Endothelial Growth Factor Vegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human vascular endothelial growth factor vegf/product/R&D Systems
Average 97 stars, based on 1 article reviews
recombinant human vascular endothelial growth factor vegf - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

94
R&D Systems vegf a 165
FAK inhibitors decrease number of viable <t>endothelial</t> cells in a dose‐dependent manner. HUVEC were incubated with various concentrations of either PF‐228 (A) or FI14 (B) in the presence of <t>VEGF.</t> Cells treated with vehicle (DMSO) were used ...
Vegf A 165, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vegf a 165/product/R&D Systems
Average 94 stars, based on 1 article reviews
vegf a 165 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
R&D Systems bt vegf a 165 r d systems
FAK inhibitors decrease number of viable <t>endothelial</t> cells in a dose‐dependent manner. HUVEC were incubated with various concentrations of either PF‐228 (A) or FI14 (B) in the presence of <t>VEGF.</t> Cells treated with vehicle (DMSO) were used ...
Bt Vegf A 165 R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bt vegf a 165 r d systems/product/R&D Systems
Average 94 stars, based on 1 article reviews
bt vegf a 165 r d systems - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

90
R&D Systems full length vegf165 his protein
FAK inhibitors decrease number of viable <t>endothelial</t> cells in a dose‐dependent manner. HUVEC were incubated with various concentrations of either PF‐228 (A) or FI14 (B) in the presence of <t>VEGF.</t> Cells treated with vehicle (DMSO) were used ...
Full Length Vegf165 His Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/full length vegf165 his protein/product/R&D Systems
Average 90 stars, based on 1 article reviews
full length vegf165 his protein - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

93
R&D Systems human vegf165
FAK inhibitors decrease number of viable <t>endothelial</t> cells in a dose‐dependent manner. HUVEC were incubated with various concentrations of either PF‐228 (A) or FI14 (B) in the presence of <t>VEGF.</t> Cells treated with vehicle (DMSO) were used ...
Human Vegf165, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human vegf165/product/R&D Systems
Average 93 stars, based on 1 article reviews
human vegf165 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
R&D Systems biotinylated vegf
( a ) G6 and 18 low-energy designs, each encoding 4–10 mutations relative to G6 (number of mutations is indicated above the bars) were tested for binding using yeast display at 8 nM <t>VEGF</t> concentration, resulting in seven designs that showed comparable or higher binding signal compared to G6. G6 des1 and G6 des13 were chosen for further characterization (colored in blue and orange, respectively). ( b ) SPR kinetic analysis of VEGF binding with twofold dilutions from a maximal concentration of 100 nM by G6, G6 des1 , and G6 des13 Fabs demonstrated faster binding on-rate in the designs ( k a = 2.3 * 10 5 M -1 s -1 , 3.27 * 10 5 M -1 s -1 and 5.3 * 10 5 M -1 s -1 , respectively). G6 des13 also improved binding off-rate ( k d = 3.2 * 10 −5 s -1 compared to 6 * 10 −5 s -1 in G6), resulting in an improved dissociation constant ( K D = 60 pM compared to 270 pM in G6). ( c & d ) Thermal denaturation and temperature of aggregation onset experiments, respectively, using microscale thermophoresis indicated substantially higher apparent stability in the designs. ( e ) Computational mutation-tolerance mapping indicated 11 positions at the vL-vH interface of the anti-VEGF antibody G6 (spheres) with potentially tolerated mutations. Thumbnails indicate selected mutations in a model structure of G6 des13 relative to G6 (gray). ( f ) Expression levels in HEK293 cells of G6 and the designs formatted as IgG were measured using Western blot analysis showing approximately an order of magnitude improvement in IgG expression levels for the designs. (g) Native mass-spectrometry analysis exhibited higher tolerance to applied collision energy in G6 des13 compared to G6, both formatted as IgG. The error bars represent standard deviations inferred from three repeats.
Biotinylated Vegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated vegf/product/R&D Systems
Average 94 stars, based on 1 article reviews
biotinylated vegf - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

90
R&D Systems zebrafish vegf a
( a ) G6 and 18 low-energy designs, each encoding 4–10 mutations relative to G6 (number of mutations is indicated above the bars) were tested for binding using yeast display at 8 nM <t>VEGF</t> concentration, resulting in seven designs that showed comparable or higher binding signal compared to G6. G6 des1 and G6 des13 were chosen for further characterization (colored in blue and orange, respectively). ( b ) SPR kinetic analysis of VEGF binding with twofold dilutions from a maximal concentration of 100 nM by G6, G6 des1 , and G6 des13 Fabs demonstrated faster binding on-rate in the designs ( k a = 2.3 * 10 5 M -1 s -1 , 3.27 * 10 5 M -1 s -1 and 5.3 * 10 5 M -1 s -1 , respectively). G6 des13 also improved binding off-rate ( k d = 3.2 * 10 −5 s -1 compared to 6 * 10 −5 s -1 in G6), resulting in an improved dissociation constant ( K D = 60 pM compared to 270 pM in G6). ( c & d ) Thermal denaturation and temperature of aggregation onset experiments, respectively, using microscale thermophoresis indicated substantially higher apparent stability in the designs. ( e ) Computational mutation-tolerance mapping indicated 11 positions at the vL-vH interface of the anti-VEGF antibody G6 (spheres) with potentially tolerated mutations. Thumbnails indicate selected mutations in a model structure of G6 des13 relative to G6 (gray). ( f ) Expression levels in HEK293 cells of G6 and the designs formatted as IgG were measured using Western blot analysis showing approximately an order of magnitude improvement in IgG expression levels for the designs. (g) Native mass-spectrometry analysis exhibited higher tolerance to applied collision energy in G6 des13 compared to G6, both formatted as IgG. The error bars represent standard deviations inferred from three repeats.
Zebrafish Vegf A, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/zebrafish vegf a/product/R&D Systems
Average 90 stars, based on 1 article reviews
zebrafish vegf a - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

93
R&D Systems hvegf
( a ) G6 and 18 low-energy designs, each encoding 4–10 mutations relative to G6 (number of mutations is indicated above the bars) were tested for binding using yeast display at 8 nM <t>VEGF</t> concentration, resulting in seven designs that showed comparable or higher binding signal compared to G6. G6 des1 and G6 des13 were chosen for further characterization (colored in blue and orange, respectively). ( b ) SPR kinetic analysis of VEGF binding with twofold dilutions from a maximal concentration of 100 nM by G6, G6 des1 , and G6 des13 Fabs demonstrated faster binding on-rate in the designs ( k a = 2.3 * 10 5 M -1 s -1 , 3.27 * 10 5 M -1 s -1 and 5.3 * 10 5 M -1 s -1 , respectively). G6 des13 also improved binding off-rate ( k d = 3.2 * 10 −5 s -1 compared to 6 * 10 −5 s -1 in G6), resulting in an improved dissociation constant ( K D = 60 pM compared to 270 pM in G6). ( c & d ) Thermal denaturation and temperature of aggregation onset experiments, respectively, using microscale thermophoresis indicated substantially higher apparent stability in the designs. ( e ) Computational mutation-tolerance mapping indicated 11 positions at the vL-vH interface of the anti-VEGF antibody G6 (spheres) with potentially tolerated mutations. Thumbnails indicate selected mutations in a model structure of G6 des13 relative to G6 (gray). ( f ) Expression levels in HEK293 cells of G6 and the designs formatted as IgG were measured using Western blot analysis showing approximately an order of magnitude improvement in IgG expression levels for the designs. (g) Native mass-spectrometry analysis exhibited higher tolerance to applied collision energy in G6 des13 compared to G6, both formatted as IgG. The error bars represent standard deviations inferred from three repeats.
Hvegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hvegf/product/R&D Systems
Average 93 stars, based on 1 article reviews
hvegf - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
R&D Systems microplate
( a ) G6 and 18 low-energy designs, each encoding 4–10 mutations relative to G6 (number of mutations is indicated above the bars) were tested for binding using yeast display at 8 nM <t>VEGF</t> concentration, resulting in seven designs that showed comparable or higher binding signal compared to G6. G6 des1 and G6 des13 were chosen for further characterization (colored in blue and orange, respectively). ( b ) SPR kinetic analysis of VEGF binding with twofold dilutions from a maximal concentration of 100 nM by G6, G6 des1 , and G6 des13 Fabs demonstrated faster binding on-rate in the designs ( k a = 2.3 * 10 5 M -1 s -1 , 3.27 * 10 5 M -1 s -1 and 5.3 * 10 5 M -1 s -1 , respectively). G6 des13 also improved binding off-rate ( k d = 3.2 * 10 −5 s -1 compared to 6 * 10 −5 s -1 in G6), resulting in an improved dissociation constant ( K D = 60 pM compared to 270 pM in G6). ( c & d ) Thermal denaturation and temperature of aggregation onset experiments, respectively, using microscale thermophoresis indicated substantially higher apparent stability in the designs. ( e ) Computational mutation-tolerance mapping indicated 11 positions at the vL-vH interface of the anti-VEGF antibody G6 (spheres) with potentially tolerated mutations. Thumbnails indicate selected mutations in a model structure of G6 des13 relative to G6 (gray). ( f ) Expression levels in HEK293 cells of G6 and the designs formatted as IgG were measured using Western blot analysis showing approximately an order of magnitude improvement in IgG expression levels for the designs. (g) Native mass-spectrometry analysis exhibited higher tolerance to applied collision energy in G6 des13 compared to G6, both formatted as IgG. The error bars represent standard deviations inferred from three repeats.
Microplate, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/microplate/product/R&D Systems
Average 93 stars, based on 1 article reviews
microplate - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc human recombinant vegf
( a ) G6 and 18 low-energy designs, each encoding 4–10 mutations relative to G6 (number of mutations is indicated above the bars) were tested for binding using yeast display at 8 nM <t>VEGF</t> concentration, resulting in seven designs that showed comparable or higher binding signal compared to G6. G6 des1 and G6 des13 were chosen for further characterization (colored in blue and orange, respectively). ( b ) SPR kinetic analysis of VEGF binding with twofold dilutions from a maximal concentration of 100 nM by G6, G6 des1 , and G6 des13 Fabs demonstrated faster binding on-rate in the designs ( k a = 2.3 * 10 5 M -1 s -1 , 3.27 * 10 5 M -1 s -1 and 5.3 * 10 5 M -1 s -1 , respectively). G6 des13 also improved binding off-rate ( k d = 3.2 * 10 −5 s -1 compared to 6 * 10 −5 s -1 in G6), resulting in an improved dissociation constant ( K D = 60 pM compared to 270 pM in G6). ( c & d ) Thermal denaturation and temperature of aggregation onset experiments, respectively, using microscale thermophoresis indicated substantially higher apparent stability in the designs. ( e ) Computational mutation-tolerance mapping indicated 11 positions at the vL-vH interface of the anti-VEGF antibody G6 (spheres) with potentially tolerated mutations. Thumbnails indicate selected mutations in a model structure of G6 des13 relative to G6 (gray). ( f ) Expression levels in HEK293 cells of G6 and the designs formatted as IgG were measured using Western blot analysis showing approximately an order of magnitude improvement in IgG expression levels for the designs. (g) Native mass-spectrometry analysis exhibited higher tolerance to applied collision energy in G6 des13 compared to G6, both formatted as IgG. The error bars represent standard deviations inferred from three repeats.
Human Recombinant Vegf, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human recombinant vegf/product/Cell Signaling Technology Inc
Average 93 stars, based on 1 article reviews
human recombinant vegf - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

96
R&D Systems rhplgf protein
( a ) G6 and 18 low-energy designs, each encoding 4–10 mutations relative to G6 (number of mutations is indicated above the bars) were tested for binding using yeast display at 8 nM <t>VEGF</t> concentration, resulting in seven designs that showed comparable or higher binding signal compared to G6. G6 des1 and G6 des13 were chosen for further characterization (colored in blue and orange, respectively). ( b ) SPR kinetic analysis of VEGF binding with twofold dilutions from a maximal concentration of 100 nM by G6, G6 des1 , and G6 des13 Fabs demonstrated faster binding on-rate in the designs ( k a = 2.3 * 10 5 M -1 s -1 , 3.27 * 10 5 M -1 s -1 and 5.3 * 10 5 M -1 s -1 , respectively). G6 des13 also improved binding off-rate ( k d = 3.2 * 10 −5 s -1 compared to 6 * 10 −5 s -1 in G6), resulting in an improved dissociation constant ( K D = 60 pM compared to 270 pM in G6). ( c & d ) Thermal denaturation and temperature of aggregation onset experiments, respectively, using microscale thermophoresis indicated substantially higher apparent stability in the designs. ( e ) Computational mutation-tolerance mapping indicated 11 positions at the vL-vH interface of the anti-VEGF antibody G6 (spheres) with potentially tolerated mutations. Thumbnails indicate selected mutations in a model structure of G6 des13 relative to G6 (gray). ( f ) Expression levels in HEK293 cells of G6 and the designs formatted as IgG were measured using Western blot analysis showing approximately an order of magnitude improvement in IgG expression levels for the designs. (g) Native mass-spectrometry analysis exhibited higher tolerance to applied collision energy in G6 des13 compared to G6, both formatted as IgG. The error bars represent standard deviations inferred from three repeats.
Rhplgf Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rhplgf protein/product/R&D Systems
Average 96 stars, based on 1 article reviews
rhplgf protein - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

Image Search Results


FAK inhibitors decrease number of viable endothelial cells in a dose‐dependent manner. HUVEC were incubated with various concentrations of either PF‐228 (A) or FI14 (B) in the presence of VEGF. Cells treated with vehicle (DMSO) were used ...

Journal: Molecular Oncology

Article Title: Focal adhesion kinase inhibitors are potent anti‐angiogenic agents

doi: 10.1016/j.molonc.2011.10.004

Figure Lengend Snippet: FAK inhibitors decrease number of viable endothelial cells in a dose‐dependent manner. HUVEC were incubated with various concentrations of either PF‐228 (A) or FI14 (B) in the presence of VEGF. Cells treated with vehicle (DMSO) were used ...

Article Snippet: Recombinant human vascular endothelial growth factor (VEGF) (rhVEGF 165 ; R&D Systems, Minneapolis, MN) was reconstituted according to the manufacturer's instructions.

Techniques: Incubation

FAK inhibitors induce cell cycle arrest and apoptosis in treated endothelial cells. Seeded HUVEC were treated with DMSO as vehicle control or varying concentrations of PF‐228 or FI14 in the presence of 50 ng/mL VEGF for 48 h. ...

Journal: Molecular Oncology

Article Title: Focal adhesion kinase inhibitors are potent anti‐angiogenic agents

doi: 10.1016/j.molonc.2011.10.004

Figure Lengend Snippet: FAK inhibitors induce cell cycle arrest and apoptosis in treated endothelial cells. Seeded HUVEC were treated with DMSO as vehicle control or varying concentrations of PF‐228 or FI14 in the presence of 50 ng/mL VEGF for 48 h. ...

Article Snippet: Recombinant human vascular endothelial growth factor (VEGF) (rhVEGF 165 ; R&D Systems, Minneapolis, MN) was reconstituted according to the manufacturer's instructions.

Techniques: Control

FAK inhibitors block HUVEC sprouting on collagen I gels. For assessing formation of sprouts, HUVEC were seeded onto collagen I gel‐coated plates and treated with 50 ng/ml VEGF in the absence (with added DMSO as a vehicle control) ...

Journal: Molecular Oncology

Article Title: Focal adhesion kinase inhibitors are potent anti‐angiogenic agents

doi: 10.1016/j.molonc.2011.10.004

Figure Lengend Snippet: FAK inhibitors block HUVEC sprouting on collagen I gels. For assessing formation of sprouts, HUVEC were seeded onto collagen I gel‐coated plates and treated with 50 ng/ml VEGF in the absence (with added DMSO as a vehicle control) ...

Article Snippet: Recombinant human vascular endothelial growth factor (VEGF) (rhVEGF 165 ; R&D Systems, Minneapolis, MN) was reconstituted according to the manufacturer's instructions.

Techniques: Blocking Assay, Control

( a ) G6 and 18 low-energy designs, each encoding 4–10 mutations relative to G6 (number of mutations is indicated above the bars) were tested for binding using yeast display at 8 nM VEGF concentration, resulting in seven designs that showed comparable or higher binding signal compared to G6. G6 des1 and G6 des13 were chosen for further characterization (colored in blue and orange, respectively). ( b ) SPR kinetic analysis of VEGF binding with twofold dilutions from a maximal concentration of 100 nM by G6, G6 des1 , and G6 des13 Fabs demonstrated faster binding on-rate in the designs ( k a = 2.3 * 10 5 M -1 s -1 , 3.27 * 10 5 M -1 s -1 and 5.3 * 10 5 M -1 s -1 , respectively). G6 des13 also improved binding off-rate ( k d = 3.2 * 10 −5 s -1 compared to 6 * 10 −5 s -1 in G6), resulting in an improved dissociation constant ( K D = 60 pM compared to 270 pM in G6). ( c & d ) Thermal denaturation and temperature of aggregation onset experiments, respectively, using microscale thermophoresis indicated substantially higher apparent stability in the designs. ( e ) Computational mutation-tolerance mapping indicated 11 positions at the vL-vH interface of the anti-VEGF antibody G6 (spheres) with potentially tolerated mutations. Thumbnails indicate selected mutations in a model structure of G6 des13 relative to G6 (gray). ( f ) Expression levels in HEK293 cells of G6 and the designs formatted as IgG were measured using Western blot analysis showing approximately an order of magnitude improvement in IgG expression levels for the designs. (g) Native mass-spectrometry analysis exhibited higher tolerance to applied collision energy in G6 des13 compared to G6, both formatted as IgG. The error bars represent standard deviations inferred from three repeats.

Journal: PLoS Computational Biology

Article Title: Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces

doi: 10.1371/journal.pcbi.1007207

Figure Lengend Snippet: ( a ) G6 and 18 low-energy designs, each encoding 4–10 mutations relative to G6 (number of mutations is indicated above the bars) were tested for binding using yeast display at 8 nM VEGF concentration, resulting in seven designs that showed comparable or higher binding signal compared to G6. G6 des1 and G6 des13 were chosen for further characterization (colored in blue and orange, respectively). ( b ) SPR kinetic analysis of VEGF binding with twofold dilutions from a maximal concentration of 100 nM by G6, G6 des1 , and G6 des13 Fabs demonstrated faster binding on-rate in the designs ( k a = 2.3 * 10 5 M -1 s -1 , 3.27 * 10 5 M -1 s -1 and 5.3 * 10 5 M -1 s -1 , respectively). G6 des13 also improved binding off-rate ( k d = 3.2 * 10 −5 s -1 compared to 6 * 10 −5 s -1 in G6), resulting in an improved dissociation constant ( K D = 60 pM compared to 270 pM in G6). ( c & d ) Thermal denaturation and temperature of aggregation onset experiments, respectively, using microscale thermophoresis indicated substantially higher apparent stability in the designs. ( e ) Computational mutation-tolerance mapping indicated 11 positions at the vL-vH interface of the anti-VEGF antibody G6 (spheres) with potentially tolerated mutations. Thumbnails indicate selected mutations in a model structure of G6 des13 relative to G6 (gray). ( f ) Expression levels in HEK293 cells of G6 and the designs formatted as IgG were measured using Western blot analysis showing approximately an order of magnitude improvement in IgG expression levels for the designs. (g) Native mass-spectrometry analysis exhibited higher tolerance to applied collision energy in G6 des13 compared to G6, both formatted as IgG. The error bars represent standard deviations inferred from three repeats.

Article Snippet: The wild-type and designed antibodies were tested for binding by flow cytometry with 8 nM biotinylated VEGF (Recombinant Human VEGF 165, Biotinylated Protein R&D systems).

Techniques: Binding Assay, Concentration Assay, Microscale Thermophoresis, Mutagenesis, Expressing, Western Blot, Mass Spectrometry